Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
By restraining T‐cell activation and promoting Treg‐cell expansion, myeloid‐derived suppressor cells (MDSCs) and tolerogenic DCs can control self‐reactive and antigraft effector T cells in autoimmunity and transplantation. Their therapeutic use and characterization, however, is limited by their scarce availability in the peripheral blood of tumor‐free donors. In the present study, we describe and characterize a novel population of human myeloid suppressor cells, named fibrocytic MDSC, which are differentiated from umbilical cord blood precursors by 4‐day culture with FDA‐approved cytokines (recombinant human‐GM‐CSF and recombinant human‐G‐CSF). This MDSC subset, characterized by the expression of MDSC‐, DC‐, and fibrocyte‐associated markers, promotes Treg‐cell expansion and induces normoglycemia in a xenogeneic mouse model of Type 1 diabetes. In order to exert their protolerogenic function, fibrocytic MDSCs require direct contact with activated T cells, which leads to the production and secretion of IDO. This new myeloid subset may have an important role in the in vitro and in vivo production of Treg cells for the treatment of autoimmune diseases, and in either the prevention or control of allograft rejection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They promote regulatory T cell (Treg) expansion and restrain T-cell activation (117)”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [117]
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationEvolving gene/transcript definitions significantly alter the interpretation of GeneChip data
Dai, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni179 · Cited by 1,797
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011
Research works printed but not linked: 1
- 10.1158/0008-5472.can-07-6621 · DOI · Paper page
Cited by
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
“Main factors implicated in MDSC-mediated immune suppression include expression of arginase (ARG1), inducible NOS (iNOS) (3–5), TGF-β (13–15), IL-10 (16), and COX2 (17–19), sequestration of cysteine (20), decreased expression of l-selectin by T cells (21), and induction of Tregs (22), among others.”
BackgroundMyeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
“More recent studies have revealed that overexpression of indoleamine 2,3-dioxygenase (IDO) or arginase 1 (ARG1) in MDSCs contributes to the mechanisms supporting T reg cell expansion in inflammatory diseases beyond cancer 53,54 .”
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
“MDSCs induce/expand Tregs in vitro and in vivo in multiple tumor models (Adeegbe et al., 2011; Huang et al., 2006; MacDonald et al., 2005; Zoso et al., 2014).”
BackgroundMyeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 458
“Indeed, these fibrocytes, mediating immune suppression via indoleamine oxidase (IDO) and Tregs expansion, have been described as a novel subset of cancer-induced MDSCs in patients with metastatic cancer [146, 147].”
BackgroundImmune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
“They promote regulatory T cell (Treg) expansion and restrain T-cell activation (117) and are associated with a number of diseases characterized by fibrosis and pathologic remodeling.”
BackgroundReprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
GM-CSF: An immune modulatory cytokine that can suppress autoimmunity
Bhattacharya, P., Thiruppathi, M., Elshabrawy, H. A., Alharshawi, K., Kumar, P., & Prabhakar, B. S. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.030 · Cited by 210
“In one study, human MDSCs derived from umbilical cord precursors with GM-CSF and G-CSF was able to prevent the development of diabetes in a xenogeneic mouse model (185).”
Myeloid suppressor cells in cancer and autoimmunity
Sica, A., & Massarotti, M. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.010 · Cited by 201
Myeloid‐derived suppressor cells: Important contributors to tumor progression and metastasis
Safarzadeh, E., Orangi, M., Mohammadi, H., Babaie, F., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26075 · Cited by 177
“reported that F-MDSCs suppress T cell proliferation through IDO (indoleamine oxidase) production and promote the expansion of Treg cells (Zoso et al., 2014).”
BackgroundAltered cancer metabolism in mechanisms of immunotherapy resistance
Ramapriyan, R., Caetano, M. S., Barsoumian, H. B., Mafra, A. C. P., Zambalde, E. P., Menon, H., Tsouko, E., Welsh, J. W., & Cortez, M. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.004 · Cited by 170
Immune suppression in chronic hepatitis B infection associated liver disease: A review
Li, T.-Y., Yang, Y., Zhou, G., & Tu, Z.-K. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i27.3527 · Cited by 163
Activation of immunosuppressive network in the aging process
Salminen, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100998 · Cited by 151
Ai, L., Mu, S., Sun, C., Fan, F., Yan, H., Qin, Y., Cui, G., Wang, Y., Guo, T., Mei, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1011-5 · Cited by 160
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Figueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R., Duckworth, A. D., Slupsky, J. R., Coulson, J. M., & Coupland, S. E. (2020) · The Journal of Pathology · doi:10.1002/path.5384 · Cited by 167
Li, F., Zhao, Y., Wei, L., Li, S., & Liu, J. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450116 · Cited by 138
“The association between tumor-infiltrating CD33CMDSC, Foxp3CTreg, IDO expression, and IDO expression in CD33CMDSCs.”
BackgroundInfluentialActivated T cells sustain myeloid-derived suppressor cell-mediated immune suppression
Pinton, L., Solito, S., Damuzzo, V., Francescato, S., Pozzuoli, A., Berizzi, A., Mocellin, S., Rossi, C. R., Bronte, V., & Mandruzzato, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6662 · Cited by 133
“IDO expression was up-regulated in MDSCs induced from healthy donor umbilical cord blood [36] and its expression was dependent on STAT3 activation [37].”
Self-citationMyeloid-Derived Suppressor Cells in Solid Tumors
Ma, T., Renz, B. W., Ilmer, M., Koch, D. T., Yang, Y., Werner, J., & Bazhin, A. V. (2022) · Cells · doi:10.3390/cells11020310 · Cited by 122
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
“cal cord blood induced selective expansion of Treg via the production of IDO upon contact with activated T cells [50].”
BackgroundSelf-citationKöstlin, N., Ostermeir, A., Spring, B., Schwarz, J., Marmé, A., Walter, C. B., Poets, C. F., & Gille, C. (2017) · European Journal of Immunology · doi:10.1002/eji.201646564 · Cited by 93
Krupa, A., & Kowalska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189879 · Cited by 101
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 93
Sun, X., Cao, Z., Mao, K., Wu, C., Chen, H., Wang, J., Wang, X., Cong, X., Li, Y., Meng, X., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119845 · Cited by 85
Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells
Hu, C., Pang, B., Lin, G., Yu, Z., & Yi, H. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0644-x · Cited by 81
The emerging role of myeloid-derived suppressor cells in lung diseases
Kolahian, S., Öz, H. H., Zhou, B., Griessinger, C. M., Rieber, N. P., & Hartl, D. (2016) · European Respiratory Journal · doi:10.1183/13993003.01572-2015 · Cited by 80
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 79
“Indeed, several studies reported the presence of an alternative MDSC subtype termed fibrocytes in patients with metastases (181, 182).”
BackgroundThe Yin and Yang of Myeloid Derived Suppressor Cells
Budhwar, S., Verma, P., Verma, R., Rai, S., & Singh, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02776 · Cited by 75
“But it is supposed that acting through IDO (indoleamine oxidase); it induces T reg population and M2 macrophages population for T cell suppression (20, 21).”
BackgroundPleyer, L., Valent, P., & Greil, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071009 · Cited by 65
“Most cells of the BM microenvironment are also pathologically altered in MDS, including ECs [120], osteoblasts [255–257], macrophages [258], and various immune cells such as NKCs [259–261], NKTs [262,263], Tregs [264–266], T-helper (Th) 1, 2, 17 and Th22 cells [264,265,267,268], CD8+ CTLs [269], DCs [270–272], and mye…”
BackgroundInfluentialSoltani, M., Zhao, Y., Xia, Z., Ganjalıkhani-Hakemi, M., & Bazhin, A. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.767026 · Cited by 68
Wang, S., Zhao, X., Wu, S., Cui, D., & Xu, Z. (2023) · Biomarker Research · doi:10.1186/s40364-023-00475-8 · Cited by 62
“Furthermore, studies in umbilical cord blood (UCB) or metastatic pediatric patients with sarcoma in the peripheral blood have identified another MDSC subgroup, named fibrocytic MDSCs (F-MDSCs) [15, 16].”
BackgroundMacrophage Implication in IPF: Updates on Immune, Epigenetic, and Metabolic Pathways
Pokhreal, D., Crestani, B., & Helou, D. G. (2023) · Cells · doi:10.3390/cells12172193 · Cited by 62
“[26,27,29] j ti s, Tumor necrosis factor alpha (TNFα) neutralization, and immune suppression uggested a limited implication of the immune system in IPF [10].”
BackgroundPark, M.-Y., Lim, B.-G., Kim, S., Sohn, H., Kim, S., & Kim, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00183 · Cited by 59
“Recently, others have reported that the fibrocytic MDSCs from CB expressed indoleamine dioxygenase (IDO), and promoted tolerance via Treg-cell expansion (18).”
BackgroundMyeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression
Cheng, J., Yuan, Y., Zhu, B., & Jia, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740827 · Cited by 58
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Cerbelli, E., Roberto, M., Giusti, R., Cortellini, A., Lionetto, L., Scagnoli, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01243 · Cited by 56
“Indeed, the interaction between MDSC and activated T cell promotes the conversion of effector T cell in Treg (31, 32).”
BackgroundInfluentialBjoern, J., Iversen, T. Z., Nitschke, N. J., Andersen, M. H., & Svane, I. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.010 · Cited by 55
Heme oxygenase and the immune system in normal and pathological pregnancies
Özen, M., Zhao, H. F., Lewis, D. B., Wong, R. J., & Stevenson, D. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00084 · Cited by 52
“MDSCs are crucial in expanding the Treg populations in a cell contact- and indoleamine 2,3-dioxygenase (IDO)-dependent manner (Zoso et al., 2014) in human cord blood.”
BackgroundClassification and biology of tumour associated stromal cells
Raffaghello, L., & Dazzi, F. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.06.016 · Cited by 66
Chen, X., Yuan, Y., Zhou, F., Li, L., Pu, J., & Jiang, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06221-y · Cited by 50
“Fibrocytic MDSCs (f-MDSCs) are a novel MDSC subset characterized by fibrocytic and MDSC surface markers with immunomodulatory properties [87].”
Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression
Yin, K., Xia, X., Rui, K., Wang, T., & Wang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610104 · Cited by 47
“Moreover, patients with advanced CRC develop resistance to chemotherapy, radiotherapy, immunotherapy and targeted drug therapy, which results in increasing challenges in treating CRC. Recently, different types of immune cells such as myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated mac…”
BackgroundInfluentialEvolving Perspectives on Innate Immune Mechanisms of IPF
Ishikawa, G., Liu, A., & Herzog, E. L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.676569 · Cited by 47
Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells
Goldmann, O., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1461455 · Cited by 47
CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor
Zilio, S., Bicciato, S., Weed, D. T., & Serafini, P. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003131 · Cited by 43
“When these cells were functionally tested in co-culture experiments with autologous, phytohem-agglutinin stimulated CFSE labeled T cells, myeloid cells from the vehicle group induced Foxp3 in most of proliferating T cells 31 whereas those from the B×471 +mara-viroc cultures expanded mostly Foxp3 -”
Self-citationKo, H., & Kim, Y. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0822-9 · Cited by 44
“In addition to PMN-MDSCs and Mo- MDSCs, fibrocytic MDSCs, which are distinguished from conventional fibrocytes, were reported in human umbilical cord blood cell culture systems (Zoso et al. 2014).”
Dynamics of the spleen and its significance in a murine H22 orthotopic hepatoma model
Li, B., Zhang, S., Huang, N., Chen, H., Wang, P., Li, J., Pu, Y., Yang, J. J., & Li, Z. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216638772 · Cited by 41
The role of myeloid‐derived suppressor cells in gastrointestinal cancer
Cui, C., Lan, P., & Fu, L. (2021) · 癌症:英文版 · doi:10.1002/cac2.12156 · Cited by 42
“Notably, MDSCs have also been found to differentiate into fibrocytes and osteoclasts in tumor mice, which may further enhance tumor growth and metastasis in cancer patients [121, 122].”
BackgroundRole of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation
Koehn, B. H., & Blazar, B. R. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr1116-464r · Cited by 42
Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives
Safari, E., Ghorghanlu, S., Ahmadi‐khiavi, H., Mehranfar, S., Rezaei, R., & Motallebnezhad, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27923 · Cited by 41
Li, X., Li, Y., Yu, Q., Qian, P., Huang, H., & Lin, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0421-597rr · Cited by 41
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
“It is important to note that the immunosuppressive activity of MDSCs is not limited to a single mechanism, with MDSCs engaging several mechanisms throughout the progression of the tumor (6, 204–206), including; (i) expansion of Tregs (207), (ii) expression of galectin-9 on the MDSC surface, resulting in T-cell apoptos…”
BackgroundNovel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment
Li, Y., He, H., Jihu, R., Zhou, J., Zeng, R., & Yan, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.698532 · Cited by 42
Tumor-Induced Myeloid-Derived Suppressor Cells
Sanctis, F. D., Bronte, V., & Ugel, S. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0016-2015 · Cited by 39
“On: Sun, 01 Sep 2019 00:57:15 4RαCD11bHLA-DR) that displayed classic fibrocyte markers, such as α smooth muscle actin and collagen I/V, possessed a potent tolerogenic activity by suppressing T-cell proliferation and promoting regulatory T cell (Treg) expansion primarily via indoleamine deoxygenase (52, 53).”
BackgroundSelf-citationEmerging Roles of Myeloid-Derived Suppressor Cells in Diabetes
Wang, S., Tan, Q., Hou, Y., & Dou, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.798320 · Cited by 37
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
Immune Cell Metabolism in Tumor Microenvironment
Li, Y., Wan, Y. Y., & Zhu, B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_5 · Cited by 37
Myeloid-derived suppressor cell: A crucial player in autoimmune diseases
Xu, D., Li, C., Xu, Y., Huang, M., Cui, D., & Xie, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021612 · Cited by 35
Nandre, R., Verma, V., Gaur, P., Patil, V., Yang, X., Ramlaoui, Z., Shobaki, N., Andersen, M. H., Pedersen, A. W., Zocca, M.-B., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0457 · Cited by 32
“Foxp3þCD4þTregs are an important element of the immunosuppressive lymphoid repertoire, which are known to be enhanced in the presence of the IDO enzyme (23).”
BackgroundMyeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer
Li, L., Li, M., & Jia, Q. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154711 · Cited by 34
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
Palumbo, G. A., Parrinello, N. L., Giallongo, C., D’Amico, E., Zanghì, A., Puglisi, F., Conticello, C., Chiarenza, A., Tibullo, D., Raimondo, F. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215459 · Cited by 34
“A third sub-type of cancer-associated fibroblasts has recently identified as CD33+CD13+CD15+IL-4Rα+CD14-CD11chiHLA-DR+ [12,13], called fibrocystic f-MDSCs for their immune-suppressive effect on T-cells, but phenotypically distinguishable from g- and mo-MDSCs [14].”
BackgroundTousif, S., Wang, Y., Jackson, J. D., Hough, K. P., Strenkowski, J. G., Athar, M., Thannickal, V. J., McCusker, R. H., Ponnazhagan, S., & Deshane, J. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747780 · Cited by 32
“It has been hypothesized that MDSCs and tumor cell-associated IDO impairs effector T cell function by promoting differentiation of Treg that support tumor progression (43, 44).”
BackgroundMesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation
Lyadova, I. V., Sosunova, E., Николаев, А. А., & Nenasheva, T. A. (2016) · Journal of Immunology Research · doi:10.1155/2016/7121580 · Cited by 31
“Different studies have associated this effect with the production of ARG-1 [67], IDO [159], IL-10 [160], CD40, and direct MDSC-Treg contacts [161, 162].”
Singh, S., Maurya, S. K., Aqdas, M., Bashir, H., Arora, A., Bhalla, V., & Agrewala, J. N. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04596-5 · Cited by 29
“Our data substantiate the previous findings that MDSCs promote Tregs during TB infection [61].”
BackgroundResultDiverse functions of myeloid-derived suppressor cells in autoimmune diseases
Xiong, X., Zhang, Y., & Wen, Y. (2023) · Immunologic Research · doi:10.1007/s12026-023-09421-0 · Cited by 28
Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche
Ya, G., Ren, W., Qin, R., He, J., & Zhao, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975261 · Cited by 29
Luo, J., Xiang, X., Gong, G., & Jiang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617662 · Cited by 32
“Besides, indoleamine 2,3-dioxygenase (IDO) or arginase 1 (ARG1) expressed by MDSCs contribute to the immunosuppressive metabolic microenvironment (59, 60).”
The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment
Hu, C., & Jiang, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.051 · Cited by 27
Mu, X., Wu, K., Zhu, Y., Zhu, Y., Wang, Y., Xiao, L., Yao, Z., Huang, W., Sun, F., Fan, J., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.06.012 · Cited by 26
Indoleamine 2,3-Dioxygenase (IDO) Regulates Th17/Treg Immunity in Experimental IgA Nephropathy
Yang, Y., Liu, K., Chen, Y., Gong, Y., & Liang, Y. (2019) · Folia Biologica · doi:10.14712/fb2019065020101 · Cited by 26
“The IDO activity could also mediate binding of ligands Toll-like receptor 9 (TLR9), cluster of differentiation 200 (CD200) and glucocorticoid-induced tumour necrosis factor receptor (GITR) on plasmacytoid dendritic cells (PDC) with their corresponding receptors on T cells to induce production of specific Treg cells (Z…”
BackgroundZhang, Q., Fujino, M., Xu, J., & Li, X. (2015) · Mediators of Inflammation · doi:10.1155/2015/421927 · Cited by 27
“This MDSC subset is characterized by the expression ofMDSC-, DC-, and fibrocyte-associatedmarkers, promoted Treg-cell expansion, and induced normoglycemia in a xenogeneic murine model of type 1 diabetes [88].”
BackgroundAbram, D. M., Fernandes, L. G. R., Filho, A. R., & Simioni, P. U. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s135367 · Cited by 22
“This biosynthesis was reduced with NF-k B blockers reinforcing the role of this factor in the induction of IDO.”
InfluentialTreg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects
Zhang, H., Felthaus, O., Eigenberger, A., Klein, S., & Prantl, L. (2024) · Cells · doi:10.3390/cells13181526 · Cited by 20
New Insights into Diabetes Cell Therapy
Lysy, P. A., Corritore, E., & Sokal, E. M. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0729-3 · Cited by 21
Cutmore, L. C., Brown, N. F., Raj, D., Chauduri, S., Wang, P., Maher, J. F., Wang, Y., Lemoine, N. R., & Marshall, J. F. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.006 · Cited by 22
Sharma, R. B., Dalmazi, G. D., & Caturegli, P. (2016) · Thyroid · doi:10.1089/thy.2016.0092 · Cited by 19
Cui, C., Zhang, T., Lin, Q., Huang, T., Rao, E., Du, J., & Fu, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.70004 · Cited by 20
IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis
Vella, V., Francesco, E. M. D., Bonavita, E., Lappano, R., & Belfiore, A. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.009 · Cited by 20
Myeloidderived suppressor cells: Escorts at the maternal–fetal interface
Pang, B., Hu, C., Li, H., Nie, X., Wang, K., Zhou, C., & Yi, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1080391 · Cited by 19
Shikonin Prolongs Allograft Survival via Induction of CD4+FoxP3+ Regulatory T Cells
Zeng, Q., Qiu, F., Chen, Y., Liu, C., Liu, H., Liang, C.-L., Zhang, Q., & Dai, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00652 · Cited by 18
“Moreover, IDO-expressing MDSCs inhibits islet xenograft rejection (42) while DCs expressing IDO also suppresses allograft rejection by expanding Tregs (43).”
BackgroundGene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs)
Mazza, E. M. C., Zoso, A., Mandruzzato, S., Bronte, V., Serafini, P., Inverardi, L., & Bicciato, S. (2014) · Genomics Data · doi:10.1016/j.gdata.2014.10.018 · Cited by 18
“We isolated and characterized a novel population of myeloid suppressor cells, named fibrocytic MDSC (f-MDSC), which are differentiated from umbilical cord blood (UCB) precursors (Zoso et al., 2014).”
BackgroundMethodSelf-citationThe Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis
Bayık, D., Lee, J., & Lathia, J. D. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_7 · Cited by 20
Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations
Gong, N., Pan, X., Deng, Y., Che, J., Bao, J., Wang, M., Xu, C., Liu, X., & Shi, Y. (2025) · MedComm · doi:10.1002/mco2.70515 · Cited by 18
Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis
Kwiatkowska, I., Hermanowicz, J. M., Przybyszewska-Podstawka, A., & Pawlak, D. (2021) · Cancers · doi:10.3390/cancers13112667 · Cited by 20
“It should be emphasized here that the latter can secrete IDO1 [43], which loops the course of events even more.”
BackgroundBizymi, N., Georgopoulou, Α., Mastrogamvraki, N., Matheakakis, A., Gontika, I., Fragiadaki, I., Mavroudi, I., & Papadaki, H. Α. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030727 · Cited by 15
“The authors propose this novel subset as a tool for the treatment of allograft rejection and in vitro generation of Tregs [70,71].”
MethodNew Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
Bizymi, N., Matthaiou, A. Μ., Matheakakis, A., Voulgari, I., Aresti, N., Zavitsanou, K., Karasachinidis, A., Mavroudi, I., Pontikoglou, C. G., & Papadaki, H. Α. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185326 · Cited by 16
“For example, they induce the development of FoxP3+ T-regs through the production of INF-γ, IL-10, and TGF-β, as well as the M2 polarisation of macrophages [66].”
MethodInfluentialMDSCs: The Key Players in the Formation of Pre-Metastatic Niche
Cui, W., Wang, Z., Lv, J., Qin, Y., & Shi, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2803058 · Cited by 16
“In addition, a novel fibrocytic MDSCs (F-MDSCs) was described in human, which share the characterization of MDSC-, DC, and fibrocyte-associated markers [6–9].”
BackgroundIL-33 Ameliorates the Development of MSU-Induced Inflammation Through Expanding MDSCs-Like Cells
Shang, K., Wei, Y., Su, Q., Yu, B., Tao, Y., He, Y., Wang, Y., Shi, G., & Duan, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00036 · Cited by 14
“Numerous studies have shown that MDSCs play a role in the regulation of effector T cells by nitric oxide production, arginase I synthesis and reactive oxygen species (ROS) production, and promoting Treg cells expansion through indoleamine-2,3-dioxygenase (IDO) production (18).”
BackgroundSimón‐Fuentes, M., Sánchez‐Ramón, S., Fernández-Paredes, L., Alonso, B., Guevara‐Hoyer, K., Vega, M. A., Corbí, A. L., & Domínguez‐Soto, Á. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01277-7 · Cited by 13
Nakao, T., Nakamura, T., Masuda, K., Matsuyama, T., Ushigome, H., Ashihara, E., & Yoshimura, N. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2017.11.014 · Cited by 12
Leverage biomaterials to modulate immunity for type 1 diabetes
Jing, Z., Li, Y., Ma, Y., Zhang, X., Liang, X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997287 · Cited by 11
“proposed a novel human MDSC subset named fibrocytic MDSC to induce Treg expansion and normoglycemia in a xenogeneic mouse model of T1D (114).”
BackgroundMyeloid-Derived Suppressor Cells and Pulmonary Hypertension
Bryant, A. J., Mehrad, B., Brusko, T. M., West, J. D., & Moldawer, L. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082277 · Cited by 11
“Related to the evolving nomenclature of the immune cell population in patients with PAH, a group has recently characterized a novel “fibrocytic MDSC” [102].”
BackgroundThe Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors
Gabrusiewicz, K. R., Colwell, N. A., & Heimberger, A. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00004-1 · Cited by 10
Phenotypic and functional dissection of myeloid-derived suppressor cells
Han, S., & Yang, Y. D. (2016) · Applied Biological Chemistry · doi:10.1007/s13765-016-0172-9 · Cited by 10
“Recently, fibrocytic MDSCs (F-MDSCs) are characterized as a novel MDSC subset in human (Abrams and Waight 2012; Zhang et al. 2013; Mazza et al. 2014; Zoso et al. 2014; Gunaydin et al. 2015).”
BackgroundActivated Circulating Myeloid-Derived Suppressor Cells in Patients with Dilated Cardiomyopathy
Zhang, W.-C., Wang, Y., Wei, W.-H., Xiong, X., Liu, K.-L., Wang, D.-H., Hu, X.-F., Peng, Y., Wu, J., & Cheng, L. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445595 · Cited by 9
Lassiter, R. L., Merchen, T. D., Fang, X., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.671025 · Cited by 9
Ghanavatinejad, A., Bozorgmehr, M., Shokri, M.-R., Aleahmad, M., Tavakoli, M., Shokri, M.-R., & Zarnani, A. (2020) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2020.103252 · Cited by 9
Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection
Shaw, J., Malherbe, S. T., Walzl, G., & du Plessis, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1222911 · Cited by 8
Benito-Lopez, J. J., Marroquin-Muciño, M., Perez-Medina, M., Chavez-Dominguez, R., Aguilar‐Cázares, D., Galicia-Velasco, M., & López-González, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1101503 · Cited by 7
Le, H., Wang, Y., Zhou, J., Li, D., Gong, Z., Zhu, F., Wang, J., Tian, C., Cai, W., & Wu, J. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.07.006 · Cited by 7
Kim, J. C., Ye, H.-J.-B., Park, I., Kim, C. W., Yoon, Y., Lee, J., Tak, K., Cho, D., Park, S. H., Kim, S.-K., et al. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26631 · Cited by 7
“what unexpected finding that might be thought to inhibit metastatic progression.(29) For example, IDO1 and kynurenine metabolites were reported to activate PI3K–Akt signaling in the neoplastic colon epithelium to promote proliferation, inhibiting apoptosis of cancer cells.”
Background
Metadata
- Authors
- Zoso, A., Mazza, E. M. C., Bicciato, S., Mandruzzato, S., Bronte, V., Serafini, P., & Inverardi, L.
- Affiliations
- University of Miami (US)
- University of Modena and Reggio Emilia (IT)
- University of Padua (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Corresponding author
- Serafini, Paolo
- Inverardi, Luca
- ORCID
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2014-10-18
- Volume
- 44
- Issue
- 11
- Pages
- 3307-3319
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1893750616
- Cited by
- 123
- References
- 46
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 15 · 2021: 17 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 8 · 2016: 13 · 2015: 11 · 2014: 1
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Susan G. Komen for the Cure
- Diabetes Research & Wellness Foundation
- Diabetes Research Foundation
- FIRB
- Foundation for Diabetes Research
- Frank Strick Foundation
- Stacy Joy Goodman Memorial Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- myeloid-derived suppressor cells, indoleamine 2,3-dioxygenase, regulatory T cells, Treg cell expansion, type 1 diabetes, normoglycemia, tolerogenic dendritic cells, T cell tolerance, allograft rejection, autoimmune disease, GM-CSF, granulocyte colony-stimulating factor, xenograft models
- MeSH terms
- Animals, Cell Differentiation, Cell Line, Diabetes Mellitus, Type 1, Female, Fetal Blood, Graft Rejection, Humans, Immune Tolerance, Lymphocyte Activation, Recombinant Proteins, Granulocyte-Macrophage Colony-Stimulating Factor, Mice, SCID, Mice, Inbred NOD, Gene Expression Profiling, Myeloid Cells, Cell Proliferation, T-Lymphocytes, Regulatory, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.